Emerging treatment options for spondyloarthritis
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 32 (3) , 472-484
Abstract
No abstract availableKeywords
Funding Information
- AbbVie, Germany
- MSD, Germany
- Pfizer, Germany
- Novartis, Germany
This publication has 66 references indexed in Scilit:
- The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritisCurrent Opinion in Rheumatology, 2014
- Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)Annals of the Rheumatic Diseases, 2014
- Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trialAnnals of the Rheumatic Diseases, 2014
- Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trialsAnnals of the Rheumatic Diseases, 2014
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2013
- IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cellsNature Medicine, 2012
- Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot studyAnnals of the Rheumatic Diseases, 2011
- Tumor necrosis factor–interleukin‐17 interplay induces S100A8, interleukin‐1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: Rationale for combination treatment during arthritisArthritis & Rheumatism, 2011
- Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trialJournal of the European Academy of Dermatology and Venereology, 2011
- Update on the therapeutic potential of PDE4 inhibitorsExpert Opinion on Investigational Drugs, 2002